| | |
| 2396 |
1:45 PM | Introduction: COX-2 Inhibitors: Where Are We Now and Where Are We Going
|
| |
1:50 PM | The Development of Cox-2 Inhibitors. J. Evans (Merck and Company, West Point, Pennsylvania, USA) |
| |
2:30 PM | Gastrointestinal, Renal and Cardiovascular Safety of Cox-2 Inhibitors. D. Metz (University of Pennsylvania, Philadelphia, Pennsylvania, USA) |
| |
2:10 PM | Analgesic and Anti Inflammatory Efficacy of Cox-2 Inhibitors. E. Hersh (University of Pennsylvania, Philadelphia, Pennsylvania, USA) |
| |
3:30 PM | Discussion |
| |
3:10 PM | The Future of Cox-2 Inhibitors: Neuroinflammation and Alxheimer's Disease. M. Kerry O'Banion (University of Rochester, New York, USA) |
| |
2:50 PM | The Future of Cox-2 Inhibitors: Colon Cancer. D. Rex (Indiana University School of Medicine, Indianapolis, Indiana, USA) |
|